tradingkey.logo

Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration

ReutersMay 27, 2025 12:17 PM

- EyePoint Pharmaceuticals Inc EYPT.O:

  • EYEPOINT COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 LUGANO TRIAL OF DURAVYU™ FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION

  • EYEPOINT PHARMACEUTICALS INC - LUCIA PHASE 3 TRIAL EXPECTED TO COMPLETE ENROLLMENT IN 3Q 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI